Metabolic aspects of polycystic ovary syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and clinical literature without systematic meta-analysis.
PubMed 42082447 · doi:10.1080/17446651.2026.2656240
What was done
Literature search across PubMed, Scopus, Google Scholar, and ScienceDirect covering clinical, experimental, and mechanistic studies published between 1985 and 2025. The narrative review evaluated the metabolic drivers of polycystic ovary syndrome (PCOS), specifically focusing on insulin resistance, hyperinsulinemia, and ovarian steroidogenesis.
What was found
The abstract reports no numerical data, effect sizes, or study counts. It qualitatively summarizes pathways through which insulin resistance and compensatory hyperinsulinemia modify ovarian steroidogenesis, impair granulosa cell aromatase activity, and disrupt follicular development, alongside systemic associations with dyslipidemia, impaired glucose tolerance, cardiovascular risk, nonalcoholic fatty liver disease, oxidative stress, and adipose tissue dysfunction.
Why it matters
It provides a synthesized conceptual framework linking endocrine and metabolic pathways in PCOS to inform targeted therapies aimed at both reproductive function and long-term cardiometabolic health.
Limits
This is a narrative review without quantitative meta-analysis, systematic screening criteria, or risk-of-bias grading. The abstract provides no primary data, sample sizes, or quantitative findings.
Cited by
- supports Lowering insulin levels reduces visceral fat, systemic inflammation, and ovarian androgen secretion.